Here are some trials that were newly posted on clinicaltrials.gov in the last 2 weeks. Most are not recruiting yet and I have no idea how long it will take before they start recruiting. The names of the drugs are in bold and I added some information that may help decide whether the trial is interesting or not.
Lorvotuzumab Mertansine (not yet recruiting)
Target: CD56
https://clinicaltrials.gov/ct2/show/NCT02452554
Relevance:
http://www.ncbi.nlm.nih.gov/pubmed/7678094
Olaratumab (not yet recruiting)
Target: PDGFRα
https://clinicaltrials.gov/ct2/show/NCT02451943
Significance:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432680/
Anlotinib (currently recruiting in China)
Target: RTK including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3)
https://clinicaltrials.gov/ct2/show/NCT02449343
PM01183 (not yet recruiting)
DNA minor groove covalent binder
https://clinicaltrials.gov/ct2/show/NCT02448537
Relevance:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998690/
PF-05082566 and KW-0761(not yet recruiting)
Immunotherapy
Target: 4-1bb
Target: Anti-CCR4 monoclonal antibody
https://clinicaltrials.gov/ct2/show/NCT02444793
TAS-119 (recruiting in UK and Netherlands)
Target: Aurora kinase A inhibitor
https://clinicaltrials.gov/ct2/show/NCT02448589
Relevance:
http://www.ncbi.nlm.nih.gov/pubmed/22244830